KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.3 million.

  • Aquestive Therapeutics' Receivables - Other rose 1637.46% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 1637.46%. This contributed to the annual value of $2.5 million for FY2024, which is 1516.3% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Receivables - Other stood at $2.3 million, which was up 1637.46% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Other peaked at $6.0 million during Q4 2021, and registered a low of $1.6 million during Q1 2024.
  • Moreover, its 5-year median value for Receivables - Other was $2.2 million (2025), whereas its average is $2.6 million.
  • In the last 5 years, Aquestive Therapeutics' Receivables - Other soared by 11880.17% in 2021 and then crashed by 6435.0% in 2022.
  • Aquestive Therapeutics' Receivables - Other (Quarter) stood at $6.0 million in 2021, then tumbled by 64.35% to $2.1 million in 2022, then surged by 36.28% to $2.9 million in 2023, then dropped by 15.16% to $2.5 million in 2024, then dropped by 6.03% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.2 million for Q2 2025, and $2.2 million during Q1 2025.